Succinimidyl succinamide

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: Succinimidyl succinamide
• 英文别名: N'-(2,5-dioxopyrrolidin-1-yl)butanediamide
• 化学式: C₈H₁₁N₃O₄
• 分子量: 213.19
• InChiKey: KQTSOJHOCCWAEH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -2.6
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  110
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• Macrocyclic compounds as inhibitors of viral replication
  申请人：Blatt M. Lawrence

  公开号：US20050267018A1

  公开（公告）日：2005-12-01

  The embodiments provide compounds of the general formulas I-XIX, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating flaviviral infection, including hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition.

  该实施例提供了一般式I-XIX的化合物，以及包括药物组合在内的组合物，其中包括一种主体化合物。该实施例还提供了治疗方法，包括治疗黄病毒感染的方法，包括丙型肝炎病毒感染的方法和治疗肝纤维化的方法，这些方法通常涉及向需要的个体施用一种主体化合物或组合物的有效量。
• CELL PENETRATING PEPTIDES WHICH BIND IRF5
  申请人：HOFFMANN-LA ROCHE INC.

  公开号：US20160009772A1

  公开（公告）日：2016-01-14

  The present invention comprises cell penetrating peptides that bind to interferon regulatory factor IRF5 and disrupt the IRF5 homo-dimerization and/or attenuate downstream signaling, and a method for screening peptides that inhibit IRF5. Generally, the cell penetrating peptides of the invention bind human interferon regulatory factor IRF5 (CPP-IRF5).

  本发明包括与干扰素调节因子IRF5结合的细胞穿透肽，破坏IRF5的同源二聚体化和/或减弱下游信号传导，以及筛选抑制IRF5的肽的方法。一般来说，本发明的细胞穿透肽与人类干扰素调节因子IRF5（CPP-IRF5）结合。
• [EN] COMPSTATIN ANALOGS WITH IMPROVED POTENCY AND PHARMACOKINETIC PROPERTIES<br/>[FR] ANALOGUES DE COMPSTATINE DE PUISSANCE ET DE PROPRIÉTÉS PHARMACOCINÉTIQUES AMÉLIORÉES
  申请人：UNIV PENNSYLVANIA

  公开号：WO2015142701A1

  公开（公告）日：2015-09-24

  Compounds comprising peptides capable of binding C3 protein and inhibiting complement activation are disclosed. The compounds include a modified compstatin peptide or analog thereof, comprising an added N-terminal component that improves (1) the binding affinity of the peptide to C3, C3b or C3c and/or (2) the plasma stability and/or plasma residence time of the peptide, as compared with an unmodified compstatin peptide under equivalent conditions. Methods of improving the C3 binding of compstatin or compstatin analogs are also disclosed, as well as methods of designing compstatin analogs with improved C3 binding.

  本发明涉及包含能够结合C3蛋白并抑制补体激活的肽的化合物。这些化合物包括一种经过修改的compstatin肽或其类似物，其中包括一个添加的N-末端组分，该组分改善了肽与C3、C3b或C3c的结合亲和力和/或与未经修改的compstatin肽在等效条件下相比的血浆稳定性和/或血浆停留时间。还公开了改善compstatin或compstatin类似物的C3结合的方法，以及设计具有改善C3结合的compstatin类似物的方法。
• AMPHIPHILIC COMPOUNDS AND SELF-ASSEMBLING COMPOSITIONS MADE THEREFROM
  申请人：Ladet Sébastien

  公开号：US20120052042A1

  公开（公告）日：2012-03-01

  The present disclosure relates to amphiphilic compounds, self assembling compositions formed from the amphiphilic compounds and methods of making such compositions.

  本公开涉及两性化合物、由两性化合物形成的自组装组合物以及制备这种组合物的方法。
• Neuropeptide-2 receptor (Y-2R) agonists and uses thereof
  申请人：Conde-Knape Karin

  公开号：US20070135351A1

  公开（公告）日：2007-06-14

  Provided herein are neuropeptide-2 receptor agonists of the formula (I): as well as pharmaceutically acceptable salts, derivatives and fragments thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of diseases such as, for example, obesity and diabetes.

  本文提供了公式（I）的神经肽2受体激动剂，以及其药学上可接受的盐，衍生物和片段，其中取代基如规范中所披露的那样。这些化合物及其包含它们的制药组合物可用于治疗肥胖症和糖尿病等疾病。